Revolution Medicines, Inc.

https://www.revmed.com

Revolution Medicines, Inc. is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for RAS-addicted cancers. The company's core mission is to revolutionize treatment for patients suffering from these cancers through the discovery, development, and delivery of innovative, targeted medicines. Revolution Medicines maintains its headquarters in Redwood City, California, United States.

The company's research and development pipeline is primarily focused on RAS(ON) Inhibitors, which are designed to suppress various oncogenic variants of RAS proteins. Key investigational therapies currently in clinical development include daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor. Additionally, RMC-5127, a RAS(ON) G12V-selective inhibitor, is also in clinical trials. These therapies aim to address cancers driven by RAS mutations, which are prevalent in pancreatic, lung, and colorectal cancers.

In recent news, on May 1, 2026, the U.S. Food and Drug Administration (FDA) granted expanded access to Revolution Medicines' investigational pancreatic cancer drug, daraxonrasib (RMC-6236), for patients with metastatic pancreatic ductal adenocarcinoma. This authorization allows for the early use of the drug outside of traditional clinical trials, highlighting the critical need for new treatments for this aggressive disease. Daraxonrasib has demonstrated promising late-stage trial data, showing a significant improvement in overall survival for previously treated patients compared to standard chemotherapy. Mark A. Goldsmith, M.D., Ph.D., leads the company as its Chief Executive Officer and Chairman. Revolution Medicines is strategically positioned as a clinical-stage oncology company specializing in direct RAS(ON) inhibition.

Latest updates

Revolution Medicines Presents Encouraging Data for RAS Inhibitor in Pancreatic Cancer

Event summary

  • Revolution Medicines presented updated Phase 1/2 clinical data for daraxonrasib, an oral RAS(ON) inhibitor, at the 2026 AACR Annual Meeting.
  • Data showed encouraging preliminary antitumor activity in both monotherapy and combination (daraxonrasib plus gemcitabine and nab-paclitaxel) cohorts for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
  • The combination therapy demonstrated a 58% objective response rate (ORR) and 6-month progression-free survival (PFS) of 84%, while monotherapy showed a 47% ORR and 6-month PFS of 71%.
  • These findings support continued evaluation of daraxonrasib in the ongoing Phase 3 RASolute 303 trial.
  • Revolution Medicines previously announced that the Phase 3 RASolute 302 trial in previously treated patients met all primary and key secondary endpoints.

The big picture

Revolution Medicines' data represents a significant step forward in targeting RAS-addicted cancers, a historically challenging area with high unmet need. Pancreatic cancer, with its low survival rates and resistance to standard therapies, represents a multi-billion dollar market opportunity. The positive signals from both monotherapy and combination data suggest a broader applicability for daraxonrasib, but the Phase 3 trial results will be the ultimate determinant of its commercial viability.

What we're watching

Clinical Validation
The success of the Phase 3 RASolute 303 trial will be critical to validating daraxonrasib's efficacy in the first-line setting and driving potential regulatory approval.
Competitive Landscape
The emergence of other RAS inhibitors will likely intensify competition and necessitate a differentiated value proposition for daraxonrasib to achieve market share.
Regulatory Pathway
The FDA's assessment of the safety and efficacy data, particularly concerning the observed adverse events, will influence the potential approval timeline and label.

Revolution Medicines Data Suggests Novel RAS Inhibitor Circumvents Resistance

Event summary

  • Revolution Medicines presented preclinical data at the 2026 AACR Annual Meeting (Abstract #6782) on a new class of mutant-targeted catalytic RAS(ON) inhibitors.
  • The lead compound, RM-055, demonstrated tumor regressions across multiple cancer types (pancreatic, lung, colorectal) in preclinical models, including those resistant to prior RAS inhibitors.
  • RM-055’s mechanism involves stimulating GTPase activity, converting mutant RAS from an active (ON) to inactive (OFF) state, a long-sought goal in RAS research.
  • The company’s cyclophilin A tri-complex platform enabled this novel mechanism, differentiating it from existing RAS-targeted therapies.

The big picture

Revolution Medicines' approach to RAS inhibition represents a significant departure from existing strategies, directly addressing the challenge of drug resistance—a major impediment to progress in RAS-addicted cancers, which collectively represent a substantial portion of cancer diagnoses. The company’s cyclophilin A tri-complex platform appears to be a key differentiator, potentially enabling a broader range of therapeutic interventions. Success hinges on demonstrating clinical efficacy and navigating a potentially complex regulatory landscape.

What we're watching

Clinical Translation
The preclinical efficacy observed with RM-055 will need to be replicated in human clinical trials to validate its potential as a meaningful therapeutic option.
Regulatory Pathway
Given the novel mechanism of action, the regulatory pathway for RM-055 may differ from that of existing RAS inhibitors, potentially impacting approval timelines.
Competitive Landscape
The emergence of this new class of catalytic inhibitors will likely intensify competition within the RAS oncology space, potentially impacting the market share of existing therapies.

Revolution Medicines Daraxonrasib Data Show Promise in Pancreatic Cancer

Event summary

  • Revolution Medicines will present Phase 3 RASolute 302 trial results for daraxonrasib at the 2026 ASCO Annual Meeting on May 31st.
  • Topline results previously indicated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy.
  • Daraxonrasib is an oral RAS(ON) multi-selective inhibitor targeting cancers with RAS mutations, including pancreatic ductal adenocarcinoma (PDAC).
  • The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with and without identified tumor RAS mutations.

The big picture

Pancreatic cancer remains a devastating disease with limited treatment options and a poor prognosis. Revolution Medicines' daraxonrasib represents a potential breakthrough by targeting the underlying RAS mutations that drive the disease in a significant portion of patients. The positive topline data, if confirmed in the full presentation, could establish daraxonrasib as a new standard of care and significantly impact the company's valuation.

What we're watching

Clinical Validation
The full presentation at ASCO will provide crucial details on the efficacy and safety data, which will determine the drug's potential for regulatory approval and market adoption.
Regulatory Pathway
Given the Breakthrough Therapy Designation, the FDA’s review timeline and potential approval criteria will be heavily influenced by the data presented at ASCO.
Competitive Landscape
The success of daraxonrasib could significantly impact the competitive dynamics in the pancreatic cancer treatment space, potentially displacing existing chemotherapy regimens.

Revolution Medicines Secures $2.2 Billion in Combined Offering

Event summary

  • Revolution Medicines closed concurrent offerings of common stock and convertible senior notes, raising approximately $2.2 billion in gross proceeds.
  • The offering included the full exercise of underwriters’ options, adding $158.45 million to the initial $2.06 billion target.
  • The notes carry a 0.50% coupon, mature in 2033, and have an initial conversion price of approximately $198.80 per share.
  • Net proceeds to Revolution Medicines are estimated at $2.137 billion, earmarked for general corporate purposes, including R&D and commercialization expenses.

The big picture

Revolution Medicines’ successful, upsized offering underscores the continued investor appetite for targeted oncology therapies, particularly those addressing the challenging RAS pathway. The combination of equity and convertible notes provides flexibility but also introduces complexities related to potential dilution and conversion dynamics. The $2.2 billion raise positions the company to aggressively pursue clinical development and potential commercialization, but execution risk remains high given the inherent challenges in oncology drug development.

What we're watching

Conversion Dynamics
The relatively high initial conversion price and the conditions for redemption suggest management may be incentivized to engineer a stock price increase to trigger conversion or redemption, potentially diluting existing shareholders.
R&D Spending
With a substantial cash infusion, the company's ability to efficiently allocate resources to its RAS inhibitor pipeline and demonstrate clinical efficacy will be critical to justifying the valuation.
Fundamental Change
The note indenture’s ‘fundamental change’ clause introduces a potential trigger for repurchase, which could create uncertainty for investors if Revolution Medicines experiences a significant shift in ownership or strategy.

Revolution Medicines Secures $2.0 Billion in Stock and Convertible Note Offering

Event summary

  • Revolution Medicines priced a concurrent public offering of 10.56 million common stock shares at $142/share, raising approximately $1.5 billion.
  • The company also issued $500 million in 0.50% convertible senior notes due 2033.
  • Both the stock and note offerings were upsized from previously announced sizes ($750 million and $250 million, respectively).
  • Revolution Medicines has a 30-day option to issue an additional 1.58 million shares.
  • Net proceeds from the offerings are estimated at $1.65 billion (including the option exercise) and will be used for general corporate purposes.

The big picture

Revolution Medicines' aggressive financing underscores the significant capital requirements in late-stage oncology drug development. The concurrent stock and note offering, while providing substantial runway, also introduces complexity with the convertible notes' conversion and redemption features. The company's valuation reflects the potential of its RAS inhibitors, but execution risk remains high given the competitive landscape and the challenges inherent in targeted cancer therapies.

What we're watching

Capital Allocation
The company's ability to effectively deploy the substantial capital raised will be critical to advancing its RAS inhibitor pipeline and achieving commercial milestones.
Conversion Dynamics
The conversion price and redemption features of the notes create a potential dilution risk for existing shareholders if the stock price remains elevated.
Regulatory Landscape
Success hinges on clinical trial outcomes and regulatory approvals for its RAS(ON) inhibitors, which face a competitive landscape and potential regulatory hurdles.

Revolution Medicines Secures $1 Billion in Combined Stock and Convertible Note Offering

Event summary

  • Revolution Medicines announced a proposed public offering of $750 million in common stock and $250 million in convertible senior notes due 2033.
  • The company has granted underwriters options to purchase up to an additional $112.5 million in stock and $37.5 million in notes to cover over-allotments.
  • The notes carry a 2033 maturity date, semi-annual interest payments, and potential conversion rights into common stock.
  • Proceeds will be used for general corporate purposes, including R&D, commercialization expenses, and capital expenditures.

The big picture

Revolution Medicines’ significant capital raise underscores the ongoing demand for targeted cancer therapies and the willingness of investors to fund companies with promising late-stage clinical assets. The inclusion of convertible notes suggests a desire to manage dilution while providing a potential upside for noteholders. The $1 billion raise positions the company to aggressively pursue clinical development and potential commercialization, but also increases pressure to deliver results.

What we're watching

Conversion Dynamics
The pricing and ultimate conversion of the notes will be a key indicator of investor confidence in Revolution Medicines’ ability to achieve milestones and increase its stock price above the 130% threshold.
Capital Allocation
How effectively Revolution Medicines deploys the substantial capital raised will be critical; investors will scrutinize R&D progress and commercialization strategies for RAS-addicted cancers.
Market Reception
The success of the offering, particularly the pricing of the notes, will reflect broader investor sentiment towards late-stage oncology companies and the perceived risk of developing targeted therapies.

Revolution Medicines' Daraxonrasib Shows Dramatic Survival Benefit in Pancreatic Cancer Trial

Event summary

  • Revolution Medicines' daraxonrasib demonstrated a median overall survival (OS) of 13.2 months versus 6.7 months for standard chemotherapy in a Phase 3 trial (RASolute 302) for metastatic pancreatic cancer.
  • The trial achieved a statistically significant hazard ratio of 0.40 (p < 0.0001) for OS, meeting both primary and key secondary endpoints (progression-free survival).
  • Daraxonrasib, a RAS(ON) inhibitor, is designed to target a broad spectrum of oncogenic RAS drivers, addressing a significant unmet need in pancreatic cancer treatment.
  • Revolution Medicines intends to submit data to regulatory authorities, including the FDA, potentially leveraging a Commissioner’s National Priority Voucher.

The big picture

Pancreatic cancer represents a significant unmet medical need, with a dismal five-year survival rate of approximately 3%. Daraxonrasib’s demonstrated survival benefit positions Revolution Medicines to potentially disrupt the current treatment paradigm, which relies heavily on cytotoxic chemotherapy. The company's acquisition of Warp Drive Bio and subsequent development of a RAS(ON) inhibitor platform underscores a strategic bet on targeting a historically ‘undruggable’ target, and this trial data validates that approach.

What we're watching

Regulatory Pathway
The FDA’s review timeline will be heavily influenced by the National Priority Voucher, potentially accelerating approval but also drawing scrutiny.
Market Adoption
The success of daraxonrasib will hinge on physician adoption and patient access, given the aggressive nature of pancreatic cancer and existing treatment options.
Pipeline Expansion
How Revolution Medicines leverages this success to advance its other RAS(ON) inhibitors and expand into other cancer types will be critical for long-term value creation.

Revolution Medicines Advances Pancreatic Cancer Trial with Daraxonrasib

Event summary

  • Revolution Medicines initiated Phase 3 clinical trial RASolute 303 on April 2, 2026.
  • The trial evaluates daraxonrasib as a monotherapy and in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
  • The trial will enroll patients irrespective of tumor RAS genotype and assess progression-free survival and overall survival as primary endpoints.
  • Daraxonrasib is one of four Phase 3 trials Revolution Medicines is currently conducting, the others targeting NSCLC.

The big picture

Pancreatic cancer represents a significant unmet medical need with a dismal five-year survival rate of only 3%. Revolution Medicines' strategy of targeting RAS-addicted cancers, which account for over 90% of PDAC cases, positions daraxonrasib as a potential breakthrough therapy. The trial's design, testing both monotherapy and combination approaches, reflects a cautious yet ambitious approach to drug development in a challenging therapeutic area.

What we're watching

Clinical Efficacy
The trial's success hinges on daraxonrasib demonstrating a statistically significant improvement in progression-free survival and overall survival compared to the standard of care, a challenging hurdle given the aggressive nature of PDAC.
Combination Therapy
The inclusion of combination therapy with gemcitabine and nab-paclitaxel will reveal whether daraxonrasib can effectively synergize with existing treatments, or if it encounters resistance mechanisms.
Genotype Independence
Given the trial's enrollment of patients irrespective of RAS genotype, the data will reveal whether daraxonrasib's efficacy is consistent across different RAS mutations or if specific genotypes exhibit greater responsiveness.

Revolution Medicines Presents Promising RAS Inhibitor Data at AACR

Event summary

  • Revolution Medicines will present nine oral and poster presentations at the 2026 AACR Annual Meeting, April 17–22.
  • New Phase 1 data for zoldonrasib (G12D-selective inhibitor) will be presented in a plenary session, targeting non-small cell lung cancer.
  • Phase 1/2 data for daraxonrasib (multi-selective inhibitor) in metastatic pancreatic ductal adenocarcinoma, including monotherapy and combination data, will be featured.
  • Research highlights a new class of mutant-targeted catalytic RAS(ON) inhibitors designed to address resistance.

The big picture

Revolution Medicines' RAS(ON) inhibitor pipeline represents a high-risk, high-reward strategy targeting a historically undruggable oncogene. While the AACR presentations offer a snapshot of progress, the company faces significant challenges in demonstrating durable efficacy and managing resistance, common pitfalls in oncology drug development. The company's valuation is heavily reliant on the success of these clinical programs, and the data presented will likely drive near-term investor sentiment.

What we're watching

Clinical Efficacy
The plenary presentation of zoldonrasib data will be critical; failure to demonstrate meaningful clinical activity could significantly impact investor confidence given the challenges in the KRAS space.
Combination Therapy
The success of daraxonrasib in combination with chemotherapy in PDAC will be a key indicator of its broader utility, as PDAC is notoriously difficult to treat.
Resistance Mitigation
The preclinical data on next-generation inhibitors designed to circumvent resistance will be scrutinized to determine if Revolution Medicines can maintain a competitive edge in the rapidly evolving RAS inhibitor landscape.

Revolution Medicines Advances Oncology Pipeline, Burns Cash at Accelerated Rate

Event summary

  • Revolution Medicines reported a net loss of $364.9 million for Q4 2025, and $1.1 billion for the full year, significantly higher than the prior year.
  • The company’s R&D expenses increased to $987.3 million for the full year 2025, driven by clinical trial and manufacturing costs for multiple drug candidates.
  • RASolute 302, a Phase 3 trial for daraxonrasib in second-line metastatic PDAC, is on track for a readout in the first half of 2026.
  • Revolution Medicines initiated RASolute 305, a Phase 3 trial of zoldonrasib in combination with standard chemotherapy for first-line metastatic PDAC.

The big picture

Revolution Medicines is aggressively pursuing a novel approach to cancer treatment by targeting RAS(ON) mutations, a strategy that has historically proven challenging. While the company has made clinical progress, the substantial R&D investment and increasing losses highlight the high-risk, high-reward nature of its pipeline. The company's reliance on partnerships, like those with Summit, Tango, and Bristol Myers Squibb, will be crucial for expanding its development efforts and sharing the financial burden.

What we're watching

Clinical Outcomes
The readout of RASolute 302 will be critical in determining the commercial viability of daraxonrasib and validating Revolution Medicines' RAS(ON) targeting strategy, given the substantial investment in the program.
Cash Burn
The company's substantial cash burn rate, coupled with the need for continued clinical development, will necessitate careful monitoring of its $2.0 billion cash position and potential for future financing.
Combination Strategy
The success of zoldonrasib and other candidates will hinge on demonstrating efficacy in combination therapies, requiring Revolution Medicines to effectively manage its collaborations and clinical trial designs.

Revolution Medicines Advances RAS Inhibitor Trial, Targets G12V Mutation

Event summary

  • Revolution Medicines initiated a Phase 1 clinical trial (RMC-5127-001) for RMC-5127, a selective inhibitor of the RAS(ON) G12V variant.
  • The trial will evaluate RMC-5127 as both a monotherapy and in combination with other treatments.
  • The trial will enroll patients with solid tumors including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non–small cell lung cancer (NSCLC).
  • RMC-5127 targets approximately 48,000 patients diagnosed annually in the U.S.

The big picture

Revolution Medicines is pursuing a differentiated strategy in oncology by targeting specific RAS mutations, a historically challenging area. The G12V mutation represents a significant unmet need, with no approved targeted therapies currently available. This trial represents a key step in validating their mutant-selective RAS(ON) inhibitor approach and expanding their pipeline beyond previously explored variants, but clinical success remains highly uncertain given the complexity of RAS biology.

What we're watching

Clinical Efficacy
The trial's early data on antitumor activity will be critical in determining RMC-5127's potential and guiding further development, given the lack of targeted therapies for G12V mutations.
Regulatory Pathway
Success in this Phase 1 trial will be essential to establishing a clear regulatory pathway for RMC-5127, particularly given the competitive landscape of RAS inhibitors.
Portfolio Expansion
The success of RMC-5127 will influence Revolution Medicines' strategy for expanding its RAS(ON) inhibitor portfolio and prioritizing development of other mutant-selective inhibitors like RMC-0708 and RMC-8839.

Revolution Medicines Secures FDA Breakthrough Therapy Designation for KRAS G12D Lung Cancer Drug

Event summary

  • Revolution Medicines’ zoldonrasib received FDA Breakthrough Therapy Designation for treating adult patients with KRAS G12D-mutated NSCLC who have failed prior anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.
  • This is the first Breakthrough Therapy Designation for a drug specifically targeting the KRAS G12D mutation in NSCLC.
  • The designation is based on data from the Phase 1 RMC-9805-001 clinical trial’s monotherapy cohort, showing encouraging antitumor activity and acceptable safety.
  • Zoldonrasib is a tri-complex inhibitor designed to selectively recognize and inhibit the active, oncogenic RAS G12D(ON) mutant.

The big picture

The Breakthrough Therapy Designation validates Revolution Medicines’ focus on targeting previously ‘undruggable’ RAS mutations, a significant unmet need in NSCLC, which accounts for a substantial portion of lung cancer diagnoses. While the designation accelerates development, the clinical trial data remains preliminary, and the success of zoldonrasib will depend on demonstrating a meaningful and durable benefit over existing therapies in a challenging patient population. This designation also highlights the growing trend of precision oncology and the increasing focus on genetically defined patient subgroups.

What we're watching

Clinical Efficacy
The success of zoldonrasib will hinge on demonstrating sustained clinical benefit in larger, controlled trials, particularly given the patient population's prior treatment resistance.
Regulatory Pathway
The FDA’s expedited review process will be closely watched, and any requests for additional data or endpoints could significantly impact the drug’s timeline.
Competitive Landscape
The emergence of other KRAS inhibitors will likely intensify competition, potentially impacting zoldonrasib’s market share and pricing strategy.

Revolution Medicines Advances Daraxonrasib Pancreatic Cancer Trial

Event summary

  • Revolution Medicines initiated enrollment in Phase 3 trial RASolute 304, evaluating daraxonrasib in patients with resectable pancreatic ductal adenocarcinoma (PDAC) following adjuvant chemotherapy.
  • The trial aims to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations.
  • Daraxonrasib is a RAS(ON) multi-selective inhibitor, targeting mutations including G12X, G13X, and Q61X.
  • This is one of four Phase 3 trials currently evaluating daraxonrasib, with three focused on PDAC and one on non-small cell lung cancer.

The big picture

Pancreatic cancer represents a significant unmet medical need with limited treatment options and a dismal five-year survival rate of only 3%. Revolution Medicines' focus on RAS-addicted cancers, a common feature in PDAC, positions daraxonrasib as a potential breakthrough therapy. The success of RASolute 304 will be critical for validating the company's RAS(ON) inhibitor platform and its broader oncology pipeline.

What we're watching

Clinical Efficacy
The trial's primary endpoint, disease-free survival, will be a key indicator of daraxonrasib's potential to meaningfully impact PDAC outcomes, given the disease's poor prognosis.
Regulatory Pathway
Success in RASolute 304 will be crucial for Revolution Medicines to secure regulatory approval for daraxonrasib, potentially opening up a significant market opportunity in a disease with high unmet need.
Competitive Landscape
The trial's results will be compared against standard observation, and the emergence of competing RAS inhibitors could impact daraxonrasib's market share and pricing strategy.
CID: 509